Article metrics
Other content recommended for you
- Should rare diseases get special treatment?
- Rare neurological diseases: a practical approach to management
- Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- Ethical issues in funding orphan drug research and development
- Orphan drugs and the NHS: should we value rarity?
- Criteria to define rare diseases and orphan drugs: a systematic review protocol
- Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU
- Commissioning for rare diseases: view from the frontline
- Effectiveness, safety and costs of orphan drugs: an evidence-based review